IRIS Studien - Literaturnachweis

1. Andresen D, Steinbeck G, Brüggemann T, Müller D, Haberl R, Behrens S, Hoffmann E, Wegschneider K, Dissmann R, Ehlers H-C. Risk stratification following myocardial infarction in the thrombolytic era. A two-step strategy using noninvasive and invasive methods. J Am Coll Cardiol 1999;33(1):131-8.
2. Bigger JT Jr, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984;69(2):250-8.
3. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997;349(9053):675-82.
4. Cheema AN, Sheu K, Parker M, Kadish AH, Goldberger JJ. Nonsustained ventricular tachycardia in the setting of acute myocardial infarction: tachycardia characteristics and their prognostic implications. Circulation 1998;98(19):2030-6.
5. Declaration of Helsinki. Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects.
   Adopted by the 18th World Medical Assembly, Helsinki, Finland, 1964 and amended by the 29th World Medical Assembly, Tokyo, Japan, October 1975, the 35th World Medical Assembly, Venice, Italy, October 1983, the 41st World Medical Assembly, Hong Kong, September 1989 and the 48th General Assembly, Somerset West, Republic of South Africa, October 1996.
6. Disegni E, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Zion M, Boyko V, Behar S. The predictive value of admission heart rate on mortality in patients with acute myocardial infarction. SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. J Clin Epidemiol 1995;48(10):1197-205.
7. Epstein AE, Hallstrom AP, Rogers WJ, Liebson PR, Seals AA, Anderson JL, Cohen JD, Capone RJ, Wyse DG. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA 1993;270(20):2451-5.
8. European Standard EN 540. Clinical investigation of medical devices for human subjects. Approved by European Committee for Standardization on June 21, 1993. Central Secretariat, Brussels
9. Geller NL and Pocock SJ. Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. Biometrics 1987;43:213-233.
10. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339(8):489-97.
11. Hartikainen JE, Malik M, Staunton A, Poloniecki J, Camm AJ. Distinction between arrhythmic and nonarrhythmic death after acute myocardial infarction based on heart rate variability, signal-averaged electrocardiogram, ventricular arrhythmias and left ventricular ejection fraction. J Am Coll Cardiol 1996;28(2):296-304.
12. Helmling E. First worldwide clinical experience with the 54 cc Micro Jewel II implantable cardioverter defibrillator. On behalf of worldwide Micro Jewel II investigators. Abstract 313, XIXth Congress of the European Society of Cardiology, Stockholm 1997, Sweden.
13. Herlitz J, Dellborg M, Karlson BW, Lindqvist J, Sanden W, Svensson H, Sjolin M, Wedel H. Similar risk reduction of death of extended-release metoprolol once daily and immediate-release metoprolol twice daily during 5 years after myocardial infarction. Cardiovasc Drugs Ther 1999;13(2):127-35.
14. Hjalmarson A, Gilpin EA, Kjekshus J, Schieman G, Nicod P, Henning H, Ross J Jr. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990;65(9):547-53.
15. Hoffmann E, Steinbeck G. Experience with pectoral versus abdominal implantation of a small defibrillator. A multicenter comparison in 778 patients. European Jewel Investigators. Eur Heart J 1998;19(7):1085-98.
16. ICH Guideline for Good Clinical Practice; IFPMA ICH Secretariat, Geneva; May 1996
17. International Standard ISO 14155. Clinical Investigation of medical devices. 1996.
18. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997;349(9053):667-74.
19. Kober L, Torp-Pedersen C, Elming H, Burchardt H. Use of left ventricular ejection fraction or wall-motion score index in predicting arrhythmic death in patients following an acute myocardial infarction. The TRACE Study Group. Pacing Clin Electrophysiol 1997;20(10 Pt 2):2553-9
20. Køber L, Torp?Pedersen C. Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study. Am J Cardiol 1995;76(1):1?5.
21. Krumholz HM, Radford MJ, Wang Y, Chen J, Heiat A, Marciniak TA. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 1998;280(7):623-9.
22. Kühlkamp VR, Volosin KJ, Hügl BJ, Stafford W, Cameron DA, Larsen JS, Cuijpers A. Worldwide experience with a new dual-chamber implantable cardioverter defibrillator (ICD). Circulation 1998;98(17, Suppl. I): I-191.
23. Lambertz H, Schweizer P, Krebs W, Merx W, Erbel R, von Essen R, Uebis R, von Erckelenz H, Meyer J, Effert S. Echokardiographische Verlaufskontrolle des akuten Myokardinfarktes nach intrakoronarer Streptolysebehandlung. Z Kardiol 1984;73(5):321-6.
24. Medizinproduktegesetz (MPG) vom 2. August 1994 (BGBl. I S. 1963), geändert durch das Erste Gesetz zur Änderung des Medizinproduktegesetzes (1.MPG-ÄndG) vom 6. August 1998 (BGBl. I S. 2005)
25. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised Intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353(9169):2001-7.
26. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335(26):1933-40.
27. O'Brien PC and Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556.
28. Pocock SJ. When to stop a clinical trial. British Medical Journal 1992;305:235-240.
29. Puri PS. Contractile and biochemical effects of coronary reperfusion after extended periods of coronary occlusion. Am J Cardiol 1975;36(2):244-51.
30. Rosenqvist M, Beyer T, Block M, den Dulk K, Minten J, Lindemans F. Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study. European 7219 Jewel ICD investigators. Circulation 1998;98(7):663-70.
31. Rustige J, Schiele R, Burczyk U, Koch A, Gottwik M, Neuhaus KL, Tebbe U, Uebis R, Senges J. The 60 minutes myocardial infarction project. Treatment and clinical outcome of patients with acute myocardial infarction in Germany. Eur Heart J 1997;18(9):1438-46.
32. Sandberg A, Ragnarsson G, Jonosson UE, Sjögren J. Design of a new multiple-unit controlled-release formulation of metoprolol: metoprolol CR. Eur J Clin Pharmacol 1988; 33 (Suppl.): S3-7.
33. Schuster S, Koch A, Burczyk U, Schiele R, Wagner S, Zahn R, Glunz HG, Heinrich F, Stuby K, Berg G, Voigtlander T, Gieseler U, Jakob M, Hauptmann P, Senges J. Frühbehandlung des akuten Myokardinfarktes: Umsetzung von Therapierichtlinien in den klinischen Alltag, MITRA?Pilotphase. Z Kardiol 1997;86(4):273?83.
34. Schuster S, Koch A, Schiele R, Burczyk U, Wagner S, Zahn R, Rustige J, Limbourg P, G lker H, Senges J. Impact of Early Risk Stratification on the Length of Hospitalization in Patients with Acute Q-Wave Myocardial Infarction. ‚The 60-minutes myocardial infarction project'. Cardiology 1998;90(3):212-219.
35. Task Force of the Working group on Arrhythmias of the European Society of Cardilology:The early termination of clinical trials: causes, consequences, and control, with special reference to trials in the field of arrhythmias and sudden death. Circulation 1994;89:2892-2907.
36. The Antiarrhythmic Versus Implantable Defibrillators (AVID) Investigators. Comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-1583
37. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321(6):406-12.
38. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996;348(9019):7-12.
    Woods KL, Ketley D, Lowy A, Agusti A, Hagn C, Kala R, Karatzas NB, Leizorowicz A, Reikvam A, Schilling J, Seabra-Gomes R, Vasiliauskas D, Wilhelmsen L. Beta-blockers and antithrombotic treatment for secondary prevention after acute myocardial infarction. Towards an understanding of factors influencing clinical practice. The European Secondary Prevention Workgroup. Eur Heart J 1998;19(1):74-9.